rituximab maintenance

DRUG2 trials

Sponsors

European Mantle Cell Lymphoma Network, Ludwig-Maximilians - University of Munich

Conditions

Lymphoma, FollicularLymphoma, Intermediate-GradeLymphoma, Low-GradeLymphoma, Mantle-Cell

Phase 3

Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL

European Mantle Cell Lymphoma NetworkLymphoma, Mantle-Cell

Start: 2004-01-14End: 2018-12-31Target: 570Updated: 2017-03-07

FCM Versus R-FCM Followed by R-Maintenance or Observation Only

Ludwig-Maximilians - University of MunichLymphoma, Follicular, Lymphoma, Intermediate-Grade, Lymphoma, Low-Grade

Start: 1998-11-30End: 2021-06-30Updated: 2021-05-07

Related Papers

Validation of POD24 As a Robust Early Clinical End Point of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials

Blood2023-11-029 citations

A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial

Cancers2021-12-3113 citations

Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial

Journal of Clinical Oncology2019-12-05134 citations

Treatment of older patients with mantle-cell lymphoma.

2012-08-01351 citations

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.

2009-12-23207 citations